D

    Design Therapeutics Inc (DSGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.09
    -0.02 (-0.13%)

    Market Cap: $945.61M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(15/22)
    Avg Surprise
    -5.34%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.35
    Range$-0.39 - $-0.33
    7 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.36-1.6%
    30d ago$-0.36-1.6%
    7d ago$-0.36-1.6%
    Current$-0.35
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    Dec 31, 2026
    EPS Consensus$-0.33
    Range$-0.60 - $-0.20
    7 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.33---
    Sep 26EST
    		-$-0.35---
    Jun 26
    		$-0.32$-0.36+11.11%Beat+5.9%
    Mar 26
    		$-0.29$-0.33+12.12%Beat+6.5%
    Dec 25
    		$-0.27$-0.33+18.18%Beat-12.5%
    Sep 25
    		$-0.30$-0.34+11.76%Beat-30.4%
    Jun 25
    		$-0.34$-0.32-6.25%Miss-61.9%
    Mar 25
    		$-0.31$-0.28-10.71%Miss-55.0%
    Dec 24
    		$-0.24$-0.27+10.01%Beat-14.3%
    Sep 24
    		$-0.23$-0.24+4.17%Beat+17.9%
    Jun 24
    		$-0.21$-0.23+8.70%Beat+41.7%
    Mar 24
    		$-0.20$-0.26+23.08%Beat+42.9%
    Dec 23
    		$-0.21$-0.31+32.26%Beat+32.3%
    Sep 23
    		$-0.28$-0.42+33.33%Beat+12.5%
    Jun 23
    		$-0.36$-0.40+10.00%Beat-33.3%
    Mar 23
    		$-0.35$-0.35+0.00%Beat-45.8%
    Dec 22
    		$-0.31$-0.34+8.82%Beat-55.0%
    Sep 22
    		$-0.32$-0.29-10.34%Miss-52.4%
    Jun 22
    		$-0.27$-0.25-8.00%Miss-92.9%
    Mar 22
    		$-0.24$-0.22-9.09%Miss+22.6%
    Dec 21
    		$-0.20$-0.23+13.04%Beat-
    Sep 21
    		$-0.21$-0.13-61.54%Miss-
    Jun 21
    		$-0.14$-0.22+36.36%Beat-
    Mar 21
    		$-0.31$-0.09-244.44%Miss-

    Key Metrics

    Valuation
    P/E Ratio-12.79EV/EBITDA-0.84x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-34.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio18.86xQuick Ratio18.86x
    Trading Statistics
    Beta1.64Avg Volume514.95K
    52-Week High$17.2552-Week Low$5.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$15.37
    SMA 20$14.81
    SMA 50$13.95
    SMA 200$11.48
    EMA 10$15.16
    EMA 20$14.75
    EMA 50$13.90
    EMA 200$11.46

    MACD

    Line: 0.56Signal: 0.59Hist: -0.03

    ADX

    ADX: 26.1+DI: 23.4-DI: 21.0

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$15.98

    Bollinger Bands

    Upper Band$16.29
    Lower Band$13.33
    %B Position2000%(Upper)
    Band Width0.59

    RSI (14-Day)

    Neutral
    57.6

    Momentum Oscillators

    Stoch %K54.7
    Stoch %D64.3
    Williams %R-49.0
    ROC (10d)-0.1%
    Momentum-0.01
    CCI (20d)14.5
    MFI (14d)43.7

    Volatility Measures

    ATR (14d)$0.71(4.7%)
    StdDev (20d)0.74
    Hist Vol35.0%(Moderate)

    Volume Flow

    VWAP$14.88
    OBV6.3M
    AD Line2.2M
    CMF (20d)0.231

    Volume Metrics

    Avg Vol (20d)516.8K
    Vol Ratio1.4x
    VWMA (20d)$14.95

    Pivot Points

    R3$15.94
    R2$15.65
    R1$15.38
    Pivot Point$15.09
    S1$14.82
    S2$14.53
    S3$14.26

    Advanced Oscillators

    TSI23.94
    Ultimate Osc53.9
    KST158.43

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$588,000$0$0$0$838,000$0
    Cost of Revenue$0$0$-14,741,000$0$0$0$149,000$0$0$0$138,000$0
    Gross Profit$0$0$14.74M$0$0$0$294,000$0$0$0$-138,000$0
    Operating Expenses$22.18M$19.71M$18.17M$19.31M$21.57M$20.42M$16.69M$16.25M$15.04M$14.40M$15.12M$18.82M
    R&D$16.39M$14.38M$13.43M$14.59M$15.74M$15.38M$12.16M$11.88M$10.52M$9.80M$11.01M$13.26M
    SG&A$5.79M$5.33M$4.74M$4.72M$5.83M$5.04M$4.54M$4.37M$4.53M$4.60M$4.11M$5.57M
    Operating Income$-22,177,000$-19,706,000$-18,169,000$-19,311,000$-21,569,000$-20,418,000$-16,694,000$-16,246,000$-15,043,000$-14,400,000$-15,121,000$-18,822,000
    Interest Income$2.01M$2.07M$2.17M$2.31M$2.49M$2.70M$3.04M$3.21M$3.25M$3.29M$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-20,165,000$-17,636,000$-15,997,000$-16,997,000$-19,083,000$-17,715,000$-13,651,000$-13,039,000$-11,793,000$-11,105,000$-11,842,000$-15,789,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-20,165,000$-17,636,000$-15,997,000$-16,997,000$-19,083,000$-17,715,000$-13,651,000$-13,039,000$-11,793,000$-11,105,000$-11,842,000$-15,789,000
    EBITDA$-22,041,000$-19,696,000$-18,525,000$-19,923,000$-22,331,000$-21,319,000$-17,983,000$-17,549,000$-16,465,000$-15,988,000$-16,819,000$-17,361,000
    EBIT$-22,177,000$-19,706,000$-18,169,000$-19,311,000$-21,569,000$-20,418,000$-16,694,000$-16,246,000$-15,043,000$-14,400,000$-15,121,000$-15,789,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DSGN

    News

    Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares

    Point72 Asset Management, along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has reported a beneficial ownership of 2,366,453 shares of Design Therapeutics, Inc. (DSGN) common stock, which represents 3.8% of the class, as of June 30, 2026. The filing indicates that while they hold shared voting and dispositive power over these shares through an investment fund, they do not claim sole power. This disclosure, made via an amended SCHEDULE 13G/A, confirms their ownership is 5 percent or less of the company.

    Stock Titan•8/14/26•
    Neutral

    Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake

    Sirenia Capital Management LP and Alex Silverstein have reported a 9.5% beneficial ownership stake in Design Therapeutics, Inc. (DSGN), totaling 5,963,936 shares, which includes shares issuable from call options. This disclosure was made in a Schedule 13G filing, indicating a passive investment purpose rather than an intent to influence control. The filing details shared voting and dispositive power over these shares, with SILV Fund, Ltd. also having rights to dividends or sale proceeds from over 5% of the outstanding common stock.

    Stock Titan•8/14/26•
    Neutral

    Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP

    Dimensional Fund Advisors LP significantly increased its stake in Design Therapeutics (NASDAQ:DSGN) by 45.0% in Q1, now owning 431,840 shares valued at $4.59 million. Other institutional investors also adjusted their holdings in the company. Design Therapeutics reported better-than-expected Q2 earnings and has an average "Moderate Buy" rating from analysts with an average price target of $16.50.

    MarketBeat•8/12/26•
    Somewhat-Bullish

    Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages

    Design Therapeutics, Inc. (NASDAQ:DSGN) has received a "Moderate Buy" consensus rating from eight brokerages, with an average 12-month price target of $16.50. The stock recently opened at $14.33, trading above its 50-day and 200-day moving averages, and institutional investors own over 56% of the company. The biopharmaceutical company focuses on developing small molecule therapeutic drugs for genetic diseases using its GeneTAC platform.

    MarketBeat•8/11/26•
    Bullish

    Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co.

    Sei Investments Co. significantly increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 152.6% in the first quarter, now holding 133,203 shares valued at approximately $1.42 million. Institutional investors collectively own 56.64% of the company. Despite reporting a quarterly EPS of negative $0.32, beating estimates, the stock carries a "Moderate Buy" consensus rating from analysts with an average price target of $16.50.

    MarketBeat•8/11/26•
    Bullish

    Frequently Asked Questions About DSGN

    Does DSGN pay dividends?
    Design Therapeutics Inc (DSGN) does not currently pay a regular dividend.
    What is DSGN's market cap?
    Design Therapeutics Inc (DSGN) has a market capitalization of $945.61M with a current stock price of $15.09.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In